Combined inhibition of TGF-β and PD-1 signaling reduces TGF-β activity in stromal cells, promotes T cell infiltration into the tumor, stimulates a robust immune response, and leads to tumor regression (126). This evidence concerns the gene TGFB1 and neoplasm.